Fundamentals for Medtronic plc
With analysts showing a buy bias for MDT, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, ...
Business Operations:
Sector: HealthcareIndustry: Medical Devices
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Revenue projections:
Financial Ratios:
| currentRatio | 2.067000 |
|---|---|
| forwardPE | 15.858396 |
| debtToEquity | 55.365000 |
| earningsGrowth | 0.407000 |
| revenueGrowth | 0.137000 |
| grossMargins | 0.652710 |
| operatingMargins | 0.193320 |
| trailingEps | 4.070000 |
| forwardEps | 6.406070 |
MDT's current ratio of 2.067, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as MDT has enough cash and current assets to handle its immediate liabilities comfortably.
MDT's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
Positive earnings and revenue growth for Medtronic plc suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
MDT's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that MDT is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.
Price projections:
Insider Transactions:
There were 5 MDT sales transactions, at market price of 90.64400024414063.No sell transactions occurred in the period under review.The trend of more buys compared to sells around MDT's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.
Recommendation changes over time:
With analysts showing a buy bias for MDT, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning MDT as a safe and profitable place for investors to allocate their funds and seek growth.